- Home
- DLY vs KURA Comparison
DLY vs KURA Comparison
Compare DLY & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DLY | KURA |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.8M | 830.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DLY | KURA |
|---|---|---|
| Price | $14.88 | $7.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $26.88 |
| AVG Volume (30 Days) | 215.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 02-25-2026 |
| Dividend Yield | ★ 8.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $104,029,000.00 |
| Revenue This Year | N/A | $88.72 |
| Revenue Next Year | N/A | $76.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.26 | $5.41 |
| 52 Week High | $15.95 | $12.49 |
Technical Indicators
Market Signals| Indicator | DLY | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 56.85 | 33.19 |
| Support Level | $14.75 | $7.36 |
| Resistance Level | $14.91 | $8.35 |
| Average True Range (ATR) | 0.09 | 0.38 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 68.97 | 15.54 |
Price Performance
Historical ComparisonAbout DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.